The New Paper

November 30, 2020

Moderna announces results from coronavirus vaccine trials

Moderna announced that its coronavirus vaccine is 94% effective based on results from late-stage clinical trials, largely confirming preliminary results released earlier this month. The company is the second to announce a vaccine with over 90% efficacy, joining Pfizer (which announced that its vaccine is 95% effective earlier this month). Moderna plans to request emergency approval from US and EU regulators today. If approved, the company expects to produce 20M vaccines this year and between 500M and 1B in 2021 (source).

More context: The Moderna vaccine uses mRNA, the same genetic tool as the vaccine developed by Pfizer and BioNTech.

This story is from the November 30, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.